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Introduction 59
Chronic pain is defined as pain lasting longer than 12 weeks. It affects around 30% of the 60 global adult population (Elzahaf, Tashani, Unsworth, & Johnson, 2012), imposes significant 61 socioeconomic burden, and contributes to excess mortality (Hocking, Morris, Dominiczak, Porteous, 62 & Smith, 2012; Vos et al., 2015) . Chronic pain is often associated with both specific and non-specific 63 medical conditions (such as cancers and HIV/AIDS, fibromyalgia and musculoskeletal conditions), 64
and with a range of injuries (Greene, 2010; Merskey & Bogduk, 1994) . It is also commonly co-65 morbid with mood disorders, such as major depressive disorder (MDD; Flint & Kendler, 2014; 66 McIntosh et al., 2016) . MDD is a common and serious mood disorder involving psychological 67 symptoms such as persistent low mood and anhedonia, and physical symptoms such as changes in 68 appetite and sleep disturbance (American Psychiatric Association 2013). In common with chronic 69 pain, MDD also imposes a significant socioeconomic burden worldwide and is now the leading cause 70 of disability globally (Vos et al., 2015) . The causal direction of factors underlying the association 71 between chronic pain and mood disorders is unclear. Chronic pain is a complex trait with moderate 72 heritability (Hocking et al., 2012) and chronic pain and MDD are genetically correlated (McIntosh et  73 al., 2016), suggesting that pleiotropic variants exist that predispose to both conditions. To date, 74 genome-wide association studies (GWAS) have not identified any genome-wide significant variants 75 associated with chronic pain at any site (Mogil, 2012 ; Zorina-Lichtenwalter, Meloto, Khoury, & 76 Diatchenko, 2016) . 77
An alternative strategy for identifying genetic variation contributing to complex traits is to 78 make use of existing GWAS summary statistic outputs within more powerful discovery approaches, 79 such as the conditional false discovery rate (cFDR) approach (Andreassen, Thompson, et al., 2013) . 80
The cFDR approach makes better use of the genetic overlap between traits or conditions to discover 81 loci based on their pleiotropic effects in each phenotype separately, as the strength of evidence for 82 involvement of a locus in a primary trait may be enhanced by consideration of the strength of 83 evidence for the same locus in an associated secondary trait. In the case of chronic pain, the 84 association with mood disorders and mood-related traits is of substantial interest, as improved 85 understanding of the biological underpinnings of this overlap may stimulate the development of novel 86 treatment strategies. 87 cFDR analyses have been used to find novel variants associated with schizophrenia, type 2 diabetes, 88
Alzheimer disease, bipolar disorder and systolic blood pressure (Andreassen, Djurovic, et al., 2013; 89 Andreassen et al., 2014; Andreassen, Thompson, et al., 2013; Wang et al., 2016) . This therefore 90 represents a promising and potentially more cost-effective method for identifying new SNPs 91 associated with complex traits by maximising the utility of existing GWAS outputs. We aimed to find 92 chronic pain-associated SNPs using cFDR analysis, with MDD as the secondary trait. In addition, we 93 sought to discover loci with pleiotropic effects on these two phenotypes. Our findings revealed six 94 novel chronic pain-associated SNPs and a locus within the LRFN5 gene where the nature of the 95 pleiotropic effects is consistent with major depression risk being mediated by genetic effects on risks 96 of chronic pain. These findings contribute to our understanding of the biological underpinnings of 97 
Data Preparation & LD Pruning 118
A dataset of SNPs for which a p-value for association, chromosome position data and rsID were 119 available in both MDD and CPG datasets was compiled. This was then LD pruned as follows. Firstly, 120 PLINK-format genotype data, for each SNP in the newly compiled CPG-MDD summary-statistic 121 dataset, was extracted from the UK Biobank genotype data (approved application 6553). Pruning was 122 carried out using command line PLINK (version 1.9) --indep-pairwise function. From each SNP-pair 123 with r 2 > 0.2 within a 50-SNP window of the lead SNP, one was removed according to PLINK's 124 greedy pruning algorithm, the window slid along 5 SNPs, and the pruning repeated. This resulted in 125 an LD-pruned dataset of 774,292 SNPs with association data available for both MDD and CPG.
Conditional False Discovery Rate (cFDR) analyses 127
cFDR is an extension of local-area false-discovery rate (FDR), which is in turn a re-thinking of 128
Benjamini & Hochberg's 'tail-end' false discovery rate procedure (Benjamini & Hochberg, 1995; 129 Efron, 2007; Liley & Wallace, 2015; Storey, 2002) . The tail-end FDR procedure is concerned with 130 controlling the FDR at a pre-defined level and deciding the maximum test statistic value from a list of 131 ordered test statistic values that allows for this (Benjamini & Hochberg, 1995) , which becomes the 132 cut-off value for deciding significance. Local FDR reframes the FDR as a Bayesian posterior 133 probability that the SNP in question is not associated with the disease or trait, given its association test 134 statistic (usually its p value) (Efron, 2007; Storey, 2002) . 135 cFDR analysis of GWAS summary statistics simply extends local FDR, with the result being the 136 posterior probability that the SNP in question is not associated with the primary phenotype, given its 137 association test statistic value for both the primary phenotype and for a secondary, related phenotype. (1) 146
The cFDR value for a SNP obtained from the above formula is the probability that the SNP is not 147 associated with the primary phenotype, given its strength of association with the secondary 148 phenotype. The ccFDR was obtained via taking the higher of the two cFDR values obtained for each 149 SNP. The significance threshold chosen was cFDR (and ccFDR) ≤0.01. 150
Genomic Context Analyses 151
The genomic context for SNPs with significant cFDR values in either analysis was examined. The R 152 
Further Exploration of Pleiotropy in LRFN5 160
Regression models were run to examine associations between genotype at a SNP identified as 161 pleiotropic in the ccFDR analysis and relevant phenotypes in data from the UK Biobank (chronic 162 pain, MDD, age attended assessment centre and sex; approved applications 10302, 6553). Genotype at 163 rs11846556 (the SNP with the lowest ccFDR) in UK Biobank individuals was coded as number of 164 effect-associated alleles (0, 1, 2 copies of the A allele). 165
Chronic pain was assessed via the question 'pain types experienced in the past month', with possible 166 answers as follows: each of 7 different body sites (multiple sites allowed), or 'all over the body', or 167 'do not know', or 'prefer not to answer'. In a separate question, the duration of any pain at the 168 reportable sites/all over the body was assessed. A dichotomous chronic pain variable was defined as 169 the presence of chronic pain in at least 1 site (or all over the body) for longer than 3 months. Those 170 who did not report pain of that duration were assigned to a control group. 
Results

207
[ Table 1 ] 208 cFDR and ccFDR analyses 209
The conditional false discovery approach was used to identify variants associated with chronic pain 210 grade, MDD, or both together in a pleiotropic fashion. Eleven SNPs in total were found at cFDR ≤ 211 0.01 (Table 1) , six of which, located on chromosomes 12 and 14, were associated with CPG and nine 212 of which, located on chromosomes 1 and 14, were associated with MDD. Four of these 11 SNPs, all 213 located within a 131 kbp region on chromosome 14, were found to be pleiotropic (ccFDR ≤0.01). 214 215
Genomic Context 216
The SNPs associated with CPG only were located close to SLC16A7 on chromosome 12 217 ( Supplementary Table 2a, 2b) , while the SNPs associated with MDD only were located within a gene-218 dense region on chromosome 1 containing LINC01360, LRRIQ3, FPGT, FPGT-TNNI3K, amongst 219 other genes ( Supplementary Table 2b ) or close to (upstream of) or within LRFN5 on chromosome 14 220
( Supplementary Table 2a, 2b) . The SNPs found to be pleiotropic were also located within LRFN5 on 221 chromosome 14 ( Supplementary Table 2a, 2b) . The pleiotropic LRFN5 SNPs were all located just 222 upstream of the 5'-most promoter, or within a large intron close to the 5'-end of the gene. The SNPs 223 associated with MDD only were also located within this intron, or were located a little further 224 upstream of the gene. The CPG-only SNPs were all located downstream of SLC16A7. One of the 225 pleiotropic SNPs on chromosome 14, rs11157241, is located approx. 30 kbp upstream of LRFN5. 226
GTeX eQTL lookups revealed that some of these phenotype-associated SNPs were also associated 227 with expression levels of nearby genes. A SNP associated only with MDD, on chromosome 1 228 (rs35641559), was found to be significantly associated with expression of a long non-coding RNA 229 gene LINC01360 in the testis (FDR < 0.05, Supplementary Table 2c ). The MDD-associated and 230 pleiotropic SNPs on chromosome 14 are all significantly associated with expression of LRFN5 in a 231 range of tissues, including brain, heart, adipose tissue and spleen ( Supplementary Table 2c ). The 232 CPG-associated SNPs on chromosome 12 were not significantly associated with expression of any 233 gene in the eQTL database ( Supplementary Table 2c ). 234
Association between rs11846556 genotype and MDD and chronic pain in UK Biobank 236
[ Table 2 ] 237
To investigate the nature of the pleiotropy revealed for variants within LRFN5, regression models 238 were used to assess the strength of association between rs11846556 genotype and each of the two 239 phenotypes of interest, chronic pain and MDD. Genotype at this SNP was associated with 240 significantly increased risk for chronic pain (Table 2a ; FDR-adjusted p = 0.0008), with each 241 additional copy of the A allele increasing the odds of having chronic pain by 2% (OR = 1.02). 242 rs11846556 genotype was also associated with chronic pain category (Table 2b) , with each additional 243 copy of the A allele associated with an OR of 1.02 per chronic pain category (FDR-adjusted p = 244 4.4x10 -5 ). Genotype at rs11846556 was not significantly associated with MDD (Table 2a ) or with 245 MDD severity (Table 2b ). rs11846556 genotype accounted for 0.29% of the variance in chronic pain 246 presence and 0.25% of the variance in chronic pain category (estimated using McFadden's R 2 , 247 adjusting for age & sex). rs11846556 genotype was no longer associated with presence of chronic 248 pain after adjustment for MDD status (FDR-adj p = 0.096), and with a larger effect size (per allele 249 betas were 0.017 vs 0.015 in the MDD-adjusted and non-adjusted models, respectively). 
Genetics of Chronic Pain & Related Disorders 255
The genetics of pain have hitherto mostly been investigated using candidate gene and animal-model In this study, the power to detect CPG-associated SNPs was increased by leveraging the additional 268 information coming from the correlation between predisposing loci for CPG and for MDD. Overall, 269
we found six CPG-associated and nine MDD-associated SNPs. In addition, pleiotropic effects of four 270 LRFN5 SNPs were observed. 271
CPG-Associated SNPs 272
The SNPs associated with CPG only were located close to SLC16A7, which encodes monocarboxylate 273 transporter 2 (MCT2). In the central nervous system, MCT2 is involved in high affinity, proton-274 coupled transport of metabolites (particularly lactate) into neurons and may play a role in neuronal 275 uptake of energy substrates released by glia (Itoh et al., 2003; Pellerin, 2003) . MCT2 is localised to 276 the post-synaptic compartment in many human neurons and may have a specialised role in synaptic 277 functioning Chiry et al., 2008, Pierre et al., 2009,) . Regulation of SLC16A7 has also been linked to 278 disorders of the brain: loss or under-expression has been associated with temporal-lobe epilepsy 279 (Lauritzen et al., 2012) and it may be expressed and methylated at different levels in psychotic 280 patients versus controls (Chen et al., 2014) . 281
MDD-Associated SNPs 282
The SNP on chromosome 1 associated with MDD only was located close to LRRIQ3 and FPGT. 283 . Additionally, differing expression patterns of LRFN5 in the brain and CNS vs the periphery 315 may be involved in opposing direction of effect associated with pleiotropic SNPs. 316
Cis-eQTLs 317
SNPs within and close to LRFN5 on chromosome 14, and in the region close to long non-coding RNA 318 gene LINC01360 on chromosome 1, were found to be cis-eQTLs. rs35641559 on chromosome 1, 319 associated with MDD only, was found to be significantly associated with LOC105378800 expression 320 levels in the testis. All four pleiotropic SNPs on chromosome 14, were found to be significantly 321 associated with LRFN5 expression levels in a range of tissues, including the brain. Further 322 investigation of potential regulatory roles for these or other nearby variants is warranted. 323
Role of rs11846556 in the biology of chronic pain and depression 324
Number of A alleles at rs11846556, one of the pleiotropic SNPs identified here, was found to be 325 associated with risk of chronic pain (and with higher values of the chronic pain category phenotype), 326
but not with MDD risk or severity (in the UK Biobank cohort), and the effect size for the chronic pain 327 association was not attenuated by inclusion of MDD in the regression model. This relationship is 328 consistent with mediated pleiotropy rather than biological pleiotropy, i.e. a pathway in which 329 genotype influences chronic pain risk, which in turn affects MDD risk, rather than influencing both by 330 separate mechanisms. Formal mediation analyses was beyond the scope of this study primarily due to 331 probable sequential ignorability violation and unmeasured confounders ( As discussed above, each of the 4 SNPs tagged as pleiotropic, including rs11846556, are also cis-334 eQTLs for LRFN5. The SNP we explored in more detail, rs11846556, is a cis-eQTL of LRFN5 in the 335 cerebellum and cerebral hemisphere, along with tibial artery (GTEx single-tissue eQTL lookup). The 336 number of A alleles at this SNP is significantly associated with increased expression of LRFN5 in 337 CNS tissues, but with a trend towards decreased expression in peripheral tissues ( Supplementary Figures 1a-d ), suggesting the existence of tissue-specific regulatory effects. This SNP is also a cis-339 eQTL for expression of a long intergenic non-coding RNA (Gencode ID: ENSG00000258636.1) on 340 the reverse strand with respect to LRFN5, but only in spleen and aorta. 341
Alterations in synaptic plasticity and neurogenesis in the hippocampus, which is often non-normal in 342 cases of neuropathic pain, may underlie some of the cognitive and affective deficits seen in patients 343 with major depression (Fasick et al 2015) . However, in cases where depression is a downstream 344 consequence of chronic pain, its onset may be influenced by lifestyle and other 'above-the-skin' 345 factors that also operate downstream of chronic pain, rather than as a more direct result of synaptic 346 changes related to LRFN5 expression levels. 347
Our data therefore suggest that rs11846556 genotype is significantly associated with chronic pain, but 348 not with MDD, and that the relationship between chronic pain and genotype is not attenuated by 349
MDD -pleiotropic effects of rs11846556 (or the functional variant it is tagging) on chronic pain and 350
MDD appear to be mediated rather than biological. Possession of more copies of the A allele at this 351 locus is associated with increased LRFN5 expression levels in the CNS, which may exert its effect on 352 transition to a chronic pain state after a prior insult through consequent alterations to brain network 353 connectivity. 354
355
Strengths and Limitations 356
A key strength of this study lies in its enhanced power, through the use of the cFDR approach, to 357 detect the contribution of genetic variants to chronic pain relative to previous genome-wide 358 approaches. Limitations include the self-reported nature of the chronic pain phenotype and the 359 somewhat general phrasing of the questions used to elicit data about this phenotype in the 23&Me and 360 UK Biobank studies, which precluded a finer dissection of the nature and severity of the pain being 361
reported. In addition, the questions asked in the two studies were slightly different, generating chronic 362 pain measures that may be capturing somewhat different aspects of the overall phenotype. 'Chronic 363 pain grade' as assessed in the Pfizer-23andMe GWAS may be capturing a more direct severity-related phenotype, whereas 'chronic pain category' as assessed in UKB is likely to be capturing a different 365 aspect of chronic pain susceptibility related to sensitivity of the response to multiple insults, or to 366 propensity to report. Despite this subtle distinction, we were able to demonstrate that an LRFN5 SNP 367 is associated with both these phenotypic pain measures. Future studies building on these findings 368 would benefit from using clinically validated or supported phenotyping data, however. 369 370
Conclusions 371
To date no common variants have been associated with presence of chronic pain at any site in the 372 body or with number of sites affected or pain severity. In this study six novel SNPs were found to be 373 associated with chronic pain grade, a measure of pain severity. cFDR analyses also increased power to 374 find MDD-associated variants in comparison to genome-wide significance thresholds. Conjunctional 375 cFDR (ccFDR) analyses revealed evidence of pleiotropic effects of variants in LRFN5. The regions 376 around the significant SNPs contain genes involved in, amongst other processes, neuronal cell 377 metabolism and development, innate immunity and cell-cell interaction. These regions have also been 378 previously implicated in a range of neurodevelopmental and psychiatric disorders. One of the 379 pleiotropic SNPs identified on chromosome 14 (rs11846556), which is a cis-eQTL of LRFN5 in 380 cerebellum and cerebral hemisphere, was found to be associated with chronic pain but not MDD in 381 UK Biobank. This provides intriguing preliminary evidence that the pleiotropy associated with 382 variation in LRFN5 may be mediated rather than horizontal. 383 384 Northwest Regional Development Agency. UK Biobank has also had funding from the Welsh 389
Assembly Government and the British Heart Foundation. Data collection was funded by UK Biobank. 
